Marksans Pharma Ltd (MARKSANS) Q1FY27 Management Mirror - Jun-2026 Qtr
FY27 Revenue Growth Guidance Reaffirmed at 15% to 20%; Q1 FY27 Margin Hits 25.3% Against Full-Year Target of 20% to 21%
In the Dec'25 Qtr concall, management guided a long-term target of reaching INR 4,000 crores in revenue in the next 2 to 3 years (by FY28 or FY29), followed by a subsequent target of INR 5,000 crores. In the Mar'26 Qtr, management reported FY26 revenue of INR 2,951 crores and an EBITDA margin of 20.4%. Concurrently, management initiated FY27 guidance, conservatively expecting top-line growth of 15% to 20% and EBITDA margins in the 20% to 21% range, while reaffirming the INR 4,000 crores revenue target by FY28. In the Jun'26 Qtr, Marksans reported Q1 FY27 revenue of 841.0 crores and an EBITDA margin of 25.3%. Management reaffirmed the FY27 guidance of 15% to 20% revenue growth and 20% to 21% EBITDA margin, adding an expectation to hit 21% to 22% margin by the end of the year. The long-term target of hitting 4,000 crores in revenue within the next two years was also reaffirmed.
4 more themes on the ELITE plan.